ArticleAntibody therapeutics2019

The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China.

Mi DengPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.